Rosetta Gets Medicare Coverage for mets2 Assay; Stock Soars | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that Novitas, a designated Medicare contractor, has informed the firm that it plans to cover its miRview mets2 assay for all Medicare beneficiaries.

Rosetta's shares climbed as high as $7.84 in Wednesday trade on the Nasdaq, before closing at $4.99, up 208 percent.

The miRview mets2 test identifies tumor of origin in primary and metastatic cancer including cancer of unknown or uncertain primary.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.